Bluejay Diagnostics, Inc.

BJDX Nasdaq CIK: 0001704287

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA, 01720
Mailing Address 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA, 01720
Phone (978) 631-0152
Fiscal Year End 1231
EIN 473552922

Financial Overview

FY2025

-$6.85M
Net Income

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 7, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
8-K Current report of material events March 16, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 11, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 11, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 11, 2026 View on SEC
10-K Annual financial report March 6, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
8-K Current report of material events February 20, 2026 View on SEC

Annual Reports

10-K March 6, 2026
  • Developing rapid, point-of-care Symphony IL-6 test for sepsis, aiming for 20-minute lab-quality results to improve patient outcomes.
  • Completed pre-clinical development of the Symphony analyzer and made significant progress in the SYMON-II pivotal clinical trial, enrolling 583 of 750 target patients.
View Analysis

Material Events

8-K Financial Distress January 30, 2026
High Impact
  • Aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
  • Maintains public listing on the Nasdaq Capital Market, supporting credibility and access to capital markets.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.